Making science workFind out how

Making science work

Find out how

APV Workshop on Protein Stability  | CN 6793

05.02. - 06.02.2020 | München, Germany


Maritim Hotel München
Goethestraße 7
80336 München

Workshop programme for download


Goals of the seminar

Therapeutic protein candidates play an increasingly important role in the pipelines of pharmaceutical companies and the marketplace for the treatment of a wide range of diseases. This conference, held under the auspices of APV (, will focus on protein stability challenges encountered during the development of these drugs. Gathering opinion leaders from academia, industry and regulatory authorities, the conference will cover a broad range of topics from what causes degradation of therapeutic proteins in formulation and processing, analytical methods of detecting aggregates and other degraded species and new approaches to stabilize and deliver protein drugs.

Options to control aggregates and particles in therapeutic protein formulation and processing will also be discussed from a hands-on experience. The seminar will also offer the opportunity to students to present their latest results in poster format, and the display of advanced analytical technology to suppliers in an industrial exhibition.

Target Group

The course is designed for all scientists involved in the development and manufacture of therapeutic proteins, working in Pharmaceutical and Biopharmaceutical Industry or at suppliers of analytical equipment or at service companies contributing, e.g. to analytical characterization of therapeutic protein drug products.
Limited places for full time students available; written evidence must be submitted.

Organising committee

  • Vasco Filipe, Sanofi, France (Chair)
  • Karoline Bechtold-Peters, Novartis, Switzerland (Chair)
  • John Carpenter, University of Colorado, USA
  • Wim Jiskoot, Leiden University, Netherlands
  • Tarik Khan, Roche, Switzerland
  • Michael Wiggenhorn, Coriolis Pharma, Germany

Abstract submission

Participants get the chance to submit abstracts for a poster presentation during the conference.The abstract should be prepared using Microsoft Word as two A4 pages typed in Times New Roman, font size 12.Please submit your abstracts by e-mail to Heide Zweyer, zweyer@apv-mainz.deDeadline for abstract submission: 30. December 2019.

Exhibition and sponsoring

For exhibition and sponsoring opportunities please get in touch with the APV headquarters, Heide Zweyer,


Karoline Bechtold-Peters, Novartis, Switzerland

Karoline Bechtold-Peters is pharmacist and holds a Doctor’s degree from the University of Munich as well as a degree as “Fachapotheker” for Pharmaceutical Technology.

She began her industrial career in 1994 at Boehringer Ingelheim in Ingelheim developing solid dosage forms with the focus on powders for inhalation (e.g. Spiriva Inhalet).
In 2000 she changed from the small molecule world to biopharmaceuticals building up Formulation Development at Boehringer Ingelheim’s Biberach site.
In 2003 Karoline took over the responsibility for global clinical supplies, aseptic process development and process transfer within Boehringer Ingelheim Biopharmaceuticals.

Beginning of 2011, Karoline joined F. Hoffmann-La Roche AG in Basel, Switzerland, where she was appointed Head of Clinical Manufacturing, Process Science and Business Excellence.

In September 2016 she moved finally to Novartis in Basel, Switzerland, as Senior Strategy & Technology Leader Pharmaceutics, Global Drug Development / TRD (Biologics) and is part of the BioFuture team.

Karoline is active in various associations (American Association of Pharmaceutical Scientists AAPS, Parenteral Drug Association PDA and International Association for Pharmaceutical Technology APV) and contributes frequently to conferences in the EU as well as in the US.

Vasco Filipe, Sanofi, France

Vasco Filipe is a Biological Engineer and obtained a Ph.D. degree in Pharmaceutical Sciences from the Utrecht University (The Netherlands) in 2011.
His thesis focused on the physicochemical characteristics, stability in biological fluids and immunogenicity of monoclonal antibody aggregates.

After a post-doc in 2012 on a similar topic, he then joined Adocia in 2013 (Lyon, France), where he worked as the Project Leader for monoclonal antibodies.

In 2015 he joined Sanofi in Paris (France), where he works as a Unit Head in the department of Pharmaceutical Development of Biologics.

Registration fee

  30.11.2019 01.12.2019
Industry 1,390.00 € 1,490.00 €
Authority / University 695.00 € 745.00 €
Students 150.00 € 178.00 €
All prices free of VAT



Dr. Martin Bornhöft
Phone: +49 6131 9769-0
Fax: +49 6131 9769-69